Imunon Q2 net loss widens slightly as R&D costs rise
IMNN•Outlook and key details
-
Imunon expects Phase 3 OVATION 3 trial enrollment to complete by first half of 2029
-
Company says OVATION 3 trial enrollment rate is exceeding internal forecasts
-
R&D spending - Higher research and development expenses linked to advancing the Phase 3 OVATION 3 trial for IMNN-001
-
Trial enrollment - Rapid enrollment and site activation in OVATION 3 trial exceeded company forecasts
-
Clinical data - Positive preliminary Phase 2 results showed deeper antitumor response and higher disease clearance rates for IMNN-001
| Metric | Actual | Consensus Estimate |
|---|---|---|
| Q2 Loss Per Share | $0.54 | |
| Q2 Net Loss | $2.80 mln | |
| Q2 Operating Expenses | $2.80 mln |
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
- The average consensus recommendation for the biotechnology & medical research peer group is "buy"
- Wall Street's median 12-month price target for Imunon Inc is $13.00, about 697.5% above its August 10 closing price of $1.63
Related News
LiqTech wins follow-on order worth over US $2 million from US steel maker for four QureFlow systems
LIQT•
Wearable Devices wins US patent for biometric authentication in gesture, voice-controlled wearables
WLDS•
